Definitive Healthcare (NASDAQ:DH) Raised to “Hold” at Zacks Research

Definitive Healthcare (NASDAQ:DH) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other equities analysts have also weighed in on the company. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Stephens lowered their price objective on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. Canaccord Genuity Group lowered their price objective on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Finally, Barclays lowered their price objective on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.27.

Definitive Healthcare Stock Performance

Definitive Healthcare stock traded down $0.01 during midday trading on Tuesday, hitting $0.93. 47,939 shares of the company were exchanged, compared to its average volume of 353,510. The firm has a market capitalization of $97.66 million, a PE ratio of -0.74, a price-to-earnings-growth ratio of 88.29 and a beta of 1.60. Definitive Healthcare has a fifty-two week low of $0.90 and a fifty-two week high of $4.70. The business has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $2.04. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.64 and a current ratio of 1.64.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of Definitive Healthcare by 32.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after buying an additional 4,407 shares during the period. State of Alaska Department of Revenue boosted its position in shares of Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after acquiring an additional 5,970 shares in the last quarter. Invesco Ltd. boosted its position in shares of Definitive Healthcare by 5.8% during the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock worth $337,000 after acquiring an additional 6,400 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Definitive Healthcare during the 2nd quarter worth about $32,000. Finally, Creative Planning boosted its position in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after acquiring an additional 8,428 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.